The Gastrointestinal Oncology Program Is a comprehensive program in gastrointestinal cancer research encompassing basic research, clinical and translational research. The program consists of 39 members from 9 different departments and two schools within the University of Michigan, receiving $9 million in annual direct support, Including $4.4 in NCl funding. The Gl grant portfolio includes a $2.1 M SPORE grant to study colorectal and pancreatic cancer, two P01 grants, UOl and U19 grants. The program is focused on the development of fundamental basic research into the causes and prevention of human gastrointestinal cancers and translational studies applying these research findings to improve the early and accurate diagnosis, evaluation, and therapeutic approaches to gastrointestinal cancer as well as Issues related to health quality outcomes, The basic research alms of the Gastrointestinal Oncology Program focus on mechanisms of cell growth and differentiation, stem cells and cell metastasis. The clinical research focuses on neoadjuvant therapies and biomarkers. The outcome research focuses on health care quality Issues. Nine new program members recruited over this grant period include Drs Marwan Fakih, Weiping Zou, Grace Chen, Chandan Kumar, Marina Pasca Di Magliano, Patrick Hu, Gazala Khan, Theodore Welling, and John Carethers. This program, which was rated as """"""""excellent"""""""" at the last core grant review, has continued to make significant strides over the past six years in each of its research goals. During the last grant period, there were a total of 302 publications from program members. The percentage of intra-programmatic and inter-programmatic publications was 15.6% and 44.7%, respectively.
The GI Oncology Program is dedicated to providing state-of-the art clinical care of patients with neoplasms of the GI tract in a multidisciplinary setting. This allows optimal tumor treatment based on input from multiple disciplines, Including surgery, medical and radiation oncology, gastroenterology, and interventional radiology. The GI oncology program also has a major focus on basic and translational research to develop a more effective approach to cancer prevention and the development of novel, more effective therapeutics.
|Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :|
|Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257|
|Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132|
|Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:|
|Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90|
|Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069|
|Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768|
|Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54|
|Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481|
|Cho, Chun-Seok; Park, Hwan-Woo; Ho, Allison et al. (2018) Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 68:1331-1346|
Showing the most recent 10 out of 1493 publications